MSD’s Keytruda Meets Endpoints in Urothelial Carcinoma Trial but Misses in NSCLC Study
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading global pharmaceutical company, last week released...
Betta Pharmaceuticals’ CFT8919 Accepted for Review by China’s NMPA for EGFR L858R Solid Tumors
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a China-based pharmaceutical company, has announced that the National...
Simcere Pharmaceutical Reports 25.2% Revenue Growth in 2023 Interim Financials
China-based Simcere Pharmaceutical Group (HKG: 2096) has released its interim financial report for 2023, revealing...
3D Medicines’ H1 2023 Report Highlights 70.3% YOY Growth in Envafolimab Sales
China-based oncology specialist 3D Medicines (HKG: 1244) has released its financial report for the first...
Acotec Scientific Holdings Receives Japanese Marketing Approval for Peripheral Support Catheter Vericor
Acotec Scientific Holdings Ltd (HKG: 6669), a China-based medical device company, has announced that it...
Chime Biologics Partners with Panolos Bioscience to Speed Up Multi-Specific Protein Development
China-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics Ltd has announced a strategic cooperation...
Hangzhou Qihan Biotechnology Secures Over $13.8 Million in Pre-Series B Financing
Hangzhou Qihan Biotechnology Co., Ltd, a leading xenotransplantation specialist based in China, has reportedly raised...
CNIPA Upholds Alynlam Pharmaceutical’s PCSK9 siRNA Patent Against Junshi Biosciences Challenge
The China National Intellectual Property Administration (CNIPA) has rejected a challenge filed by Junshi Biosciences...
Everest Medicines Partners with Kezar Life Sciences to Commercialize Zetomipzomib in Asia
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced a strategic collaboration and license...
I-Mab Regains Global Rights to CD47 Antibody Lemzoparlimab Following AbbVie Deal Termination
China-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has received a notice from US-based AbbVie Global Enterprises...
Sanofi’s Dupixent Secures NMPA Approval for Pruritigo Nodosa Treatment in China
France-based pharmaceutical company Sanofi (NASDAQ: SNY) has announced that it has received another indication approval...
EU Chamber of Commerce in China Releases Position Paper, Addresses Pharma and Healthcare
The EU Chamber of Commerce in China has released its bi-annual “European Business in China...
Eli Lilly Sues US Sellers of Counterfeit Mounjaro Products
Pharmaceutical giant Eli Lilly (NYSE: LLY) has filed a lawsuit in the United States against...
Gurnet Point Capital and Novo Holdings Acquire Paratek Pharmaceuticals for $462 Million
Healthcare fund Gurnet Point Capital (GPC) and Novo Holdings, the controlling shareholder of Novo Nordisk...
MicroPort Scientific Reports 19% Revenue Growth in H1 2023, Driven by Diverse Interventions
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has released its financial report for...
Amgen Launches Global Collaboration Network to Advance Oncology Research
Amgen (NASDAQ: AMGN) has announced the launch of a new collaboration network that connects its...
Roche’s Genentech Partners with Orionis Biosciences for Molecular Glue Therapies
Genentech, a subsidiary of Swiss pharmaceutical giant Roche (SWX: ROG), has announced a partnership with...
Suzhou Zelgen Biopharmaceuticals’ ZG005 Receives NMPA Approval for Solid Tumor Trial
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based pharmaceutical company, has announced that it...
Antengene’s Anti-CD24 Antibody ATG-031 Gets Green Light for Phase I Study at MD Anderson
Antengene Corporation Ltd (HKG: 6996), a China-based biopharmaceutical company, has announced that the Institutional Review...
Inmagene Biopharmaceuticals and Aditum Bio Launch JV Celexor Bio to Target Autoimmune Diseases
Inmagene Biopharmaceuticals, a China-based biopharmaceutical company, has announced a strategic collaboration with US firm Aditum...